To compare the effect of two drugs on recovery of normal mental state in abdominal surgery cases.

To compare the effect of remimazolam and midazolam on cognitive recovery in upper gastro intestinal endoscopic procedures. - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/109605

Enrollment

Registered

2026-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Midazolam 0.03 0.05 mg/kg: Midazolam 0.03 0.05 mg/kg will be given to the patient for upper gastro intestinal endoscopy procedure for 1 hour Control Intervention1: Remimazolam 5mg intra

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA Physical Status I or II. 2. Scheduled for elective day care surgery under sedation. 3. Ability to understand and complete cognitive tests. 4. Informed written consent.

Exclusion criteria

Exclusion criteria: 1. Known allergy to benzodiazepines. 2. ASA Physical Status III or IV. 3. Neurological or psychiatric illness 4. Chronic use of CNS depressants or sedatives. 5. History of substance abuse. 6. Pregnancy or lactation. 7. Severe hepatic or renal impairment.

Design outcomes

Primary

Measure	Time frame
Remimazolam is expected to be superior to midazolam in terms of cognitive recovery, orientation, and discharge readiness in day care surgical patients.Timepoint: Assessment will be done at 12 months.	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Vivek Chakole

Datta Meghe Institute of Higher Education and Research

hod.anesthesiajnmc@gmail.com8002784980

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026